^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Lung Adenocarcinoma
    Drug Class:Immunotherapy +
    Angiogenesis inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    BMC Pulm Med
    Title:

    Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study

    Published date:
    05/19/2023
    Excerpt:
    Of the 85 NSCLC patients with ICIs combined antiangiogenic therapy, 28 achieved PR, 43 achieved SD, and 14 achieved PR. The ORR was 32.9%, and the DCR was 83.5% (Table 5). PD-LI expression was associated with treatment responses in advanced NSCLC patients (p = 0.000), both in adenocarcinoma (p = 0.007) and squamous cell carcinoma (p = 0.049).
    DOI:
    https://doi.org/10.1186/s12890-023-02470-z